收费全文 | 34180篇 |
免费 | 2712篇 |
国内免费 | 1212篇 |
耳鼻咽喉 | 339篇 |
儿科学 | 346篇 |
妇产科学 | 233篇 |
基础医学 | 7124篇 |
口腔科学 | 769篇 |
临床医学 | 3027篇 |
内科学 | 5067篇 |
皮肤病学 | 243篇 |
神经病学 | 4890篇 |
特种医学 | 1529篇 |
外国民族医学 | 1篇 |
外科学 | 4186篇 |
综合类 | 3663篇 |
现状与发展 | 6篇 |
预防医学 | 1177篇 |
眼科学 | 609篇 |
药学 | 3357篇 |
7篇 | |
中国医学 | 1098篇 |
肿瘤学 | 433篇 |
2024年 | 70篇 |
2023年 | 534篇 |
2022年 | 709篇 |
2021年 | 1307篇 |
2020年 | 1227篇 |
2019年 | 1164篇 |
2018年 | 1164篇 |
2017年 | 1005篇 |
2016年 | 931篇 |
2015年 | 1017篇 |
2014年 | 1767篇 |
2013年 | 2079篇 |
2012年 | 1602篇 |
2011年 | 1789篇 |
2010年 | 1511篇 |
2009年 | 1501篇 |
2008年 | 1483篇 |
2007年 | 1586篇 |
2006年 | 1366篇 |
2005年 | 1223篇 |
2004年 | 1145篇 |
2003年 | 1124篇 |
2002年 | 924篇 |
2001年 | 782篇 |
2000年 | 676篇 |
1999年 | 635篇 |
1998年 | 731篇 |
1997年 | 743篇 |
1996年 | 626篇 |
1995年 | 544篇 |
1994年 | 482篇 |
1993年 | 444篇 |
1992年 | 423篇 |
1991年 | 415篇 |
1990年 | 348篇 |
1989年 | 326篇 |
1988年 | 287篇 |
1987年 | 263篇 |
1986年 | 204篇 |
1985年 | 327篇 |
1984年 | 249篇 |
1983年 | 163篇 |
1982年 | 234篇 |
1981年 | 207篇 |
1980年 | 154篇 |
1979年 | 137篇 |
1978年 | 130篇 |
1977年 | 103篇 |
1976年 | 101篇 |
1975年 | 42篇 |
Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone and provides an evaluation of the clinical usefulness of vilazodone for the treatment of MDD and anxiety disorders. A literature search was performed using PubMed/MEDLINE, Web of Science and the Cochrane Library.
Expert opinion: Studies have shown that vilazodone is significantly superior to placebo. However, vilazodone cannot as yet be recommended as a first-line treatment option for MDD as it is unclear whether the drug’s dual mechanism of action provides greater efficacy than prevailing treatment options. Moreover, more phase IV studies are needed to establish its efficacy and long-term safety in larger and more diverse populations. Although vilazodone may have an additional advantage for the treatment of anxiety symptoms in MDD, here also additional studies are required to confirm its efficacy over and above SSRI alternatives and other antidepressant treatments. Therefore, presently, vilazodone should be considered as a second- or third-line treatment option for MDD and GAD. 相似文献
Objectives
Short successive periods of skeletal muscle disuse have been suggested to substantially contribute to the observed loss of skeletal muscle mass over the life span. Hospitalization of older individuals due to acute illness, injury, or major surgery generally results in a mean hospital stay of 5 to 7 days, during which the level of physical activity is strongly reduced. We hypothesized that hospitalization following elective total hip arthroplasty is accompanied by substantial leg muscle atrophy in older men and women.Design and participants
Twenty-six older patients (75 ± 1 years) undergoing elective total hip arthroplasty participated in this observational study.Measurements
On hospital admission and on the day of discharge, computed tomographic (CT) scans were performed to assess muscle cross-sectional area (CSA) of both legs. During surgery and on the day of hospital discharge, a skeletal muscle biopsy was taken from the m. vastus lateralis of the operated leg to assess muscle fiber type–specific CSA.Results
An average of 5.6 ± 0.3 days of hospitalization resulted in a significant decline in quadriceps (?3.4% ± 1.0%) and thigh muscle CSA (?4.2% ± 1.1%) in the nonoperated leg (P < .05). Edema resulted in a 10.3% ± 1.7% increase in leg CSA in the operated leg (P < .05). At hospital admission, muscle fiber CSA was smaller in the type II vs type I fibers (3326 ± 253 μm2 vs 4075 ± 279 μm2, respectively; P < .05). During hospitalization, type I and II muscle fiber CSA tended to increase, likely due to edema in the operated leg (P = .10).Conclusions
Six days of hospitalization following elective total hip arthroplasty leads to substantial leg muscle atrophy in older patients. Effective intervention strategies are warranted to prevent the loss of muscle mass induced by short periods of muscle disuse during hospitalization. 相似文献Methods: [11C]WAY100635, [18F]altanserin and positron emission tomography were used to compare 5-HT1A and 5-HT2A binding in MDD patients divided into eight past suicide attempters (>4yrs prior to scanning) and eight lifetime non-attempters, and both groups were compared to eight healthy volunteers.
Results: The two receptor types differed in binding pattern across brain regions from each other, but there were no differences in binding between healthy volunteers and the two depressed groups or between depressed suicide attempters and non-attempters. No effects of depression severity or lifetime aggression were observed for either receptor.
Conclusion: Limitations of this study include small sample size and absence of high lethality suicide attempts in the depressed attempter group. No trait-like binding correlations with past suicide attempt or current depression were observed. Given the heterogeneity of nonfatal suicidal behavior, a larger sample study emphasizing higher lethality suicide attempts may find the serotonin biological phenotype seen in suicide decedents. 相似文献